ACADIA Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon. Thanks for joining us. We're pleased to have the ACADIA team with us where we have Steve Davis, CEO; and Elena Ridloff, CFO.
With that, Steve, I'm going to turn it over to you for any opening comments, and then I'll get into questions.
Yes, that sounds great, Salveen. Thanks much, and I'll just start with a few level-setting brief comments, then we'll get right to the Q&A.
So I'll start just by highlighting the 3 pillars of our business. First pillar is we're driving NUPLAZID growth in Parkinson's disease psychosis. In the first quarter of 2021, we achieved net sales of $106.6 million. This represents an 18% year-over-year growth. We continue to add new prescribers and new patients and continue to also see very high adherence among our continuing PD psychosis patients. And although we experienced some COVID-related headwinds in the beginning of the year, as did, I think, the entire
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
